Comparing Effectiveness Rituximab (Mabthera®) to Other Second-line Biologics for Rheumatoid Arthritis Treatment in Patients Refractory to or Intolerant of First-line Anti-tumor Necrosis Factor Agent: An Observational Study
-
- Journal of Rheumatic Diseases
- /
- v.24 no.4
- /
- pp.227-235
- /
- 2017